Prophylactic prostatectomy for prostate cancer (PPPC)
Research type
Research Study
Full title
Assessing the acceptability of prophylactic prostatectomy for people at high genetic risk of developing prostate cancer: a qualitative study
IRAS ID
333215
Contact name
Elizabeth Bancroft
Contact email
Sponsor organisation
The Royal Marsden NHS Foundation Trust
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Prostate cancer affects 1-in-8 people assigned male at birth in the UK and kills almost 12,000 annually. Half the cases occur due to genetic factors. These include rare highly-penetrant mutations such as BRCA2 as well as a combination of common genetic variants. A ‘polygenic risk score’ can be used to identify people who may develop more aggressive forms of the disease.
Prophylactic, or ‘risk-reducing’ mastectomy and oophorectomy has been shown to prevent mortality and be acceptable for healthy women with known genetic risks. There is no such evidence as yet of the benefits of similar surgery for people at a higher genetic risk of developing prostate cancer. However, this question is often posed in clinic by people who carry pathogenic variants in BRCA2. In the future we propose to develop a feasibility study offering prophylactic prostatectomy to people based on their high genetic risk (combined high polygenic risk score and BRCA2 carrier status).
Prior to this, we wish to undertake this pilot qualitative study to better understand patients’ perspectives on the acceptability of the procedure. Prostatectomy carries risks, with potential impact on erectile function and urinary continence. In this year-long project we will conduct up to 20 semi-structured interviews with patients and public to explore acceptability and to identify informational and support needs envisaged by men contemplating prophylactic prostatectomy.
We will invite people aged over 18 to take part. We will include a wide range of perspectives including those at higher genetic risk or a strong family history of prostate cancer, as well as those with unknown or normal genetic risk factors. We will include people from different socio-economic backgrounds and those of black ethnicity who carry a higher risk. They will be recruited from existing prostate cancer screening studies and from community organisations with expertise in working with under-served communities.REC name
HSC REC A
REC reference
24/NI/0072
Date of REC Opinion
28 May 2024
REC opinion
Further Information Favourable Opinion